AIRS Medical Receives FDA Clearance for SwiftSight Body Composition AI Software for Muscle and Fat Quantification

Amériquesdernières nouvellesSanté numériqueImagingProduits et technologies

AIRS Medical has received U.S. Food and Drug Administration (FDA) 510(k) clearance for SwiftSight Body Composition, an AI-powered MRI analysis solution that quantifies muscle and adipose tissue from MR images. The software measures visceral and subcutaneous fat, abdominal and thigh muscle, muscle quality, and bilateral muscle balance, along with quantitative assessment of liver fat.

The solution is built around a scan of less than five minutes followed by automated AI analysis. AI-driven segmentation quantifies body composition measurements, benchmarked against age- and sex-matched reference populations, with the resulting Body Composition Report bringing together quantitative measurements, percentile rankings, and visual summaries in one standardized view.

Designed to fit into high-volume MRI operations, SwiftSight Body Composition gives health systems and imaging networks a practical way to scale quantitative body composition across existing MRI infrastructure. Organizations can add the service without introducing a separate imaging modality or building a new manual analysis workflow, while automated AI analysis helps deploy the same capability across multiple locations with a consistent patient experience.

Body weight and BMI cannot show how fat and muscle are distributed throughout the body, and SwiftSight provides quantitative information about visceral and subcutaneous fat, muscle quantity and quality, bilateral muscle balance, and liver fat, giving healthcare professionals a more detailed view of body composition. The solution evaluates core muscles including the abdominal wall, psoas, and paraspinal muscles, as well as the quadriceps, hamstrings, and adductors, with liver fat quantified using proton density fat fraction with automated region-of-interest measurements and visual mapping.

SwiftSight Body Composition – Drive Growth with MRI Body Composition: Add AI-powered quantitative body composition analysis to existing MRI services and create new revenue opportunities from the MRI infrastructure already in operation.

For imaging organizations, SwiftSight Body Composition creates an opportunity to expand the value of existing MRI programs, with whole-body and preventive imaging, healthy-aging, weight-management, and wellness programs extended with a differentiated quantitative service. Because MRI does not use ionizing radiation, SwiftSight can also support repeat quantitative assessment over time.

The clearance expands AIRS Medical’s quantitative MRI portfolio beyond brain imaging and advances a broader platform strategy spanning MRI acquisition, workflow automation, quantitative analysis, and longitudinal measurement. The SwiftSight roadmap is expected to continue expanding, with diffusion tensor imaging planned for November 2026 and quantitative joint applications planned for 2027.

Jina Park, Chief Strategy Officer at AIRS Medical, said body composition becomes more meaningful when people can track change over time, which requires an exam that is fast and practical to repeat. Park noted that this is why SwiftSight Body Composition was built around a scan of less than five minutes, and that whether the goal is preventive health, weight management, or longevity, people taking a more active role in their health should have a quantitative measurement they can return to over time.

Ajit Shankaranarayanan, PhD, Chief Product Officer at AIRS Medical, said the next phase of MRI is not just better images but standardized quantitative information that can scale across an imaging organization. Shankaranarayanan noted that SwiftSight Body Composition is part of that shift, and that by automating the analysis of muscle, adipose tissue, and liver fat, the company is making advanced quantitative assessment easier to integrate into routine MRI workflows and creating a foundation for additional measurement capabilities across the SwiftSight platform.